Q&A: How Genomics Companies Can Prepare to Face the FDA | GenomeWeb

NEW YORK, April 13 - Recently, a number of genomics companies have announced bold new initiatives to use the genomics picks and shovels they market for their own drug discovery efforts.

But these companies may hit a drug discovery brick wall if they do not learn how to successfully negotiate the Food and Drug Administration approval phase, according to Attorney Edward Basile, a former FDA official who now heads the FDA practice group of Washington law firm King & Spalding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."